IL325865A - Compositions for delivery of plasmodium antigens and related methods - Google Patents

Compositions for delivery of plasmodium antigens and related methods

Info

Publication number
IL325865A
IL325865A IL325865A IL32586526A IL325865A IL 325865 A IL325865 A IL 325865A IL 325865 A IL325865 A IL 325865A IL 32586526 A IL32586526 A IL 32586526A IL 325865 A IL325865 A IL 325865A
Authority
IL
Israel
Prior art keywords
delivery
compositions
related methods
plasmodium antigens
plasmodium
Prior art date
Application number
IL325865A
Other languages
Hebrew (he)
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of IL325865A publication Critical patent/IL325865A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL325865A 2023-07-21 2024-07-19 Compositions for delivery of plasmodium antigens and related methods IL325865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515079P 2023-07-21 2023-07-21
PCT/US2024/038904 WO2025024335A2 (en) 2023-07-21 2024-07-19 Compositions for delivery of plasmodium antigens and related methods

Publications (1)

Publication Number Publication Date
IL325865A true IL325865A (en) 2026-03-01

Family

ID=92295739

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325865A IL325865A (en) 2023-07-21 2024-07-19 Compositions for delivery of plasmodium antigens and related methods

Country Status (4)

Country Link
CN (1) CN121816193A (en)
AU (1) AU2024301077A1 (en)
IL (1) IL325865A (en)
WO (1) WO2025024335A2 (en)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5809076A (en) 1993-03-31 1998-09-15 Panasonic Technologies, Inc. Method for automatically independently providing asynchronous brouter address information to remote control units
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
JP2002502831A (en) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション Systemic delivery of serum-stable plasmid lipid particles for the treatment of cancer
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
ATE490267T1 (en) 2001-06-05 2010-12-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT CODING A VIRAL ANTIGEN
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
ES2559828T3 (en) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. RNA interference encapsulated in lipids
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
ES2646630T3 (en) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Amino alcoholic lipidoids and uses thereof
HUE037082T2 (en) 2008-11-10 2018-08-28 Arbutus Biopharma Corp New lipids and preparations for the delivery of therapeutic agents
MX342785B (en) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc IMPROVED LIPID FORMULATION.
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
ES2613498T3 (en) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. New lipid formulations for the delivery of therapeutic agents to solid tumors
EP2506879A4 (en) 2009-12-01 2014-03-19 Protiva Biotherapeutics Inc Snalp formulations containing antioxidants
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
CA2784568A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Lipid particles for delivery of nucleic acids
US8736243B2 (en) 2009-12-19 2014-05-27 Lanery Mgmt. Limited Liability Company Control multiplexor for a switch mode power supply
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
SG186085A1 (en) 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
PL3586861T3 (en) 2011-06-08 2022-05-23 Translate Bio, Inc. COMPOSITIONS OF LIPID nanoparticles and MRN DELIVERY METHODS
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
EP2788006B1 (en) 2011-12-07 2026-01-07 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP2788316B1 (en) 2011-12-07 2019-04-24 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
CN104114572A (en) 2011-12-16 2014-10-22 现代治疗公司 Modified nucleosides, nucleotides and nucleic acid compositions
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014008334A1 (en) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
MX2016005238A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Lipid formulations for delivery of messenger rna.
SMT202200502T1 (en) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
LT3313829T (en) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACID DELIVERY
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
EP3416681B1 (en) 2016-02-17 2026-01-21 DayLife LLC Novel antigen for use in malaria vaccine
BR112018069417A2 (en) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh method to provide simple ribbon and ssrna rna
GB201615298D0 (en) * 2016-09-08 2016-10-26 Oxford Univ Innovation Ltd And Yeda Res And Dev Company Treatment and prevention of Malaria
BR112019008481A2 (en) 2016-10-26 2020-03-03 Curevac Ag LIPID NANOPARTICLE MRNA VACCINES
ES3063077T3 (en) 2016-10-26 2026-04-15 Acuitas Therapeutics Inc Lipid nanoparticle formulations
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
CN118207228B (en) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 A multi-stage dual-target tandem malaria mRNA vaccine combining prevention and treatment

Also Published As

Publication number Publication date
WO2025024335A3 (en) 2025-03-06
CN121816193A (en) 2026-04-07
AU2024301077A1 (en) 2026-01-08
WO2025024335A2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
GB2605538B (en) Compositions and methods for delivery of RNA
IL316504A (en) Rna compositions for delivery of monkeypox antigens and related methods
IL289902A (en) Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
EP4117684A4 (en) Compositions and methods for enhanced delivery of antiviral agents
IL304123A (en) Compositions and methods for delivery of rna
EP4415690A4 (en) Compositions and methods for delivery of agents
IL314324A (en) Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
AU2021413753A9 (en) Compositions and methods for delivery of rna
IL316049A (en) Pharmaceutical compositions of mosunetuzumab and methods of use
IL318706A (en) Compositions and methods for inducing ferroptosis
IL319410A (en) Compositions for delivery of plasmodium csp antigens and related methods
IL325865A (en) Compositions for delivery of plasmodium antigens and related methods
IL325898A (en) Compositions for delivery of plasmodium antigens and related methods
IL315862A (en) Angiotensinogen-modulating compositions and methods of use thereof
IL319414A (en) Compositions for delivery of liver stage antigens and related methods
CA3299278A1 (en) Compositions for delivery of plasmodium antigens and related methods
CA3299613A1 (en) Compositions for delivery of plasmodium antigens and related methods
HK40130252A (en) Compositions for delivery of plasmodium csp antigens and related methods
CA3267971A1 (en) Compositions for delivery of plasmodium csp antigens and related methods
LT4027976T (en) Rifabutin compositions and method of making
EP4522724A4 (en) Lipid compositions and methods of producing same
IL319195A (en) Compositions and methods for delivery of rna
EP4312805A4 (en) Image guided delivery of compositions and related methods
GB2593260B (en) Coupon wafer and method of preparation thereof
GB2595948B (en) Coupon wafer and method of preparation thereof